Sentence examples for maintenance for patients from inspiring English sources

The results indicated that single capecitabine maintenance for patients obtained CR, PR, or SD after short-term CapeOx provided an effective and tolerable therapeutic option.

Targeted therapies could play a part in the treatment of refractory osteosarcomas or in maintenance for patients with a high risk of relapse.

Whereas other maintenance strategies have not been widely taken up, thalidomide maintenance for patients who have achieved a response is appealing because of its multiple modes of action, especially its immunomodulatory effect.

The CHOP-OR study is a prospective phase II study to evaluate the safety, feasibility and activity of a CHOP chemotherapy in combination with ofatumumab in induction and subsequent maintenance for patients with newly diagnosed RS.

NICE analysis of the same strategy (erlotinib maintenance for patients with advanced NSCLC and stable disease after four cycles of platinum-induction therapy) calculated respective ICER of £44,812 and £68,120 per QALY for squamous and non-squamous NSCLC patients [ 27].

Two competing strategies for these patients were compared: 1) routine follow-up for all patients (Control strategy) and 2) routine follow-up plus gefitinib maintenance for patients with EGFR mutation-positive tumors and routine follow-up only for patients with EGFR mutation-negative tumors (Gefitinib strategy).

These findings are consistent with the randomized PRIMA study, which demonstrated a significantly prolonged PFS with 2 years of R-maintenance for patients with advanced stage untreated FL who responded to an R-based induction therapy.

Therefore, based on these considerations, it may be preferable to utilize buprenorphine maintenance treatment rather than methadone maintenance treatment for patients with HIV disease and opioid dependence.

Tailored collaborative care interventions with maintenance therapies for patients who recovered from a depressive disorder but who are experiencing pain might reduce recurrence risk in this particular subpopulation of vulnerable patients.

We aimed to estimate the incremental cost-effectiveness of erlotinib 150 mg/day versus best supportive care when used as first-line maintenance therapy for patients with locally advanced or metastatic NSCLC and stable disease.

The objective of this analysis was to estimate the cost-effectiveness of erlotinib versus best supportive care when used as first-line maintenance therapy for patients with locally advanced or metastatic NSCLC and stable disease following first-line therapy in three European countries, ie, France, Germany, and Italy.